Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients

TAP-144-SR (3M) is a 3-month sustained releasing injection of a super-active agonist of luteinizing hormone releasing hormone (LH-RH), leuprorelin acetate. At the Department of Urology of Gunma University Hospital, TAP-144-SR (3M) was injected once subcutaneously into 10 prostatic cancer patients wh...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hinyokika kiyo. Acta urologica Japonica. - 1962. - 48(2002), 12 vom: 28. Dez., Seite 771-9
1. Verfasser:	Koiso, Kenkichi (VerfasserIn)
Weitere Verfasser:	Yamanaka, Hidetoshi, Ito, Kazuto, Yoshinaka, Ryoji, Uchida, Satoshi, Yokokawa, Kiyoshi
Format:	Aufsatz
Sprache:	Japanese
Veröffentlicht:	2002
Zugriff auf das übergeordnete Werk:	Hinyokika kiyo. Acta urologica Japonica
Schlagworte:	Clinical Trial English Abstract Journal Article Antineoplastic Agents, Hormonal Delayed-Action Preparations Gonadotropin-Releasing Hormone 33515-09-2 Testosterone 3XMK78S47O Leuprolide EFY6W0M8TG